1. Home
  2. NBH vs PRQR Comparison

NBH vs PRQR Comparison

Compare NBH & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NBH
  • PRQR
  • Stock Information
  • Founded
  • NBH 2002
  • PRQR 2012
  • Country
  • NBH United States
  • PRQR Netherlands
  • Employees
  • NBH N/A
  • PRQR N/A
  • Industry
  • NBH Finance/Investors Services
  • PRQR Biotechnology: Pharmaceutical Preparations
  • Sector
  • NBH Finance
  • PRQR Health Care
  • Exchange
  • NBH Nasdaq
  • PRQR Nasdaq
  • Market Cap
  • NBH 288.5M
  • PRQR 179.1M
  • IPO Year
  • NBH N/A
  • PRQR 2014
  • Fundamental
  • Price
  • NBH $9.87
  • PRQR $2.35
  • Analyst Decision
  • NBH
  • PRQR Strong Buy
  • Analyst Count
  • NBH 0
  • PRQR 8
  • Target Price
  • NBH N/A
  • PRQR $8.88
  • AVG Volume (30 Days)
  • NBH 85.9K
  • PRQR 357.1K
  • Earning Date
  • NBH 01-01-0001
  • PRQR 08-07-2025
  • Dividend Yield
  • NBH 4.34%
  • PRQR N/A
  • EPS Growth
  • NBH N/A
  • PRQR N/A
  • EPS
  • NBH 0.12
  • PRQR N/A
  • Revenue
  • NBH N/A
  • PRQR $21,212,711.00
  • Revenue This Year
  • NBH N/A
  • PRQR N/A
  • Revenue Next Year
  • NBH N/A
  • PRQR N/A
  • P/E Ratio
  • NBH $87.04
  • PRQR N/A
  • Revenue Growth
  • NBH N/A
  • PRQR 85.91
  • 52 Week Low
  • NBH $8.75
  • PRQR $1.07
  • 52 Week High
  • NBH $11.01
  • PRQR $4.62
  • Technical
  • Relative Strength Index (RSI)
  • NBH 47.91
  • PRQR 66.90
  • Support Level
  • NBH $9.79
  • PRQR $2.10
  • Resistance Level
  • NBH $9.97
  • PRQR $2.18
  • Average True Range (ATR)
  • NBH 0.06
  • PRQR 0.13
  • MACD
  • NBH 0.01
  • PRQR 0.01
  • Stochastic Oscillator
  • NBH 44.44
  • PRQR 56.92

About NBH Neuberger Berman Municipal Fund Inc.

Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.

About PRQR ProQR Therapeutics N.V.

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.

Share on Social Networks: